TRITON2 enrolled a total of 277 patients with mCRPC progressing to at least an ARSI and one taxane-based chemotherapy harboring at least one P/LPV in one of the 15 selected DDR-related genes (BRCA1, BRCA2, ATM, CDK12, CHEK2, PALB2, FANCA, BARD1, BRIP1, NBN, RAD51, RAD51B, RAD51C, RAD51D, and RAD54L) detected through the genomic profiling of either cfDNA or FFPE tumor tissue by Foundation Medicine, Inc. or by local testing. This evidence concerns the gene RAD51C and neoplasm.